Reframe Daily—curated by Christin Chong (neuroscience PhD, Buddhist chaplain, healthtech strategy consultant)—delivers optimistic and credible health research updates you won’t find in most popular news outlets, from sources scientists and healthcare providers read and trust.

Today in one sentence: A mustard enzyme helped people absorb more sulforaphane from broccoli extract, a probiotic cut a harmful kidney-related blood toxin, an early DMT IV trial improved depression scores, and two new drug ideas showed promise in mice for COVID and weight gain.

Good news: People absorbed about twice as much of a helpful broccoli compound (sulforaphane) when the broccoli extract was paired with a mustard-seed enzyme in a randomized clinical study.

Exogenous myrosinase from mustard seed increases bioavailability of sulforaphane from a glucoraphanin-rich broccoli seed extract in a randomized clinical study

Market readiness: 🙂🙂🙂🙂🙂 (Food/supplement ingredients already sold in the US; this study tested a specific combo.)

Good news: A daily probiotic capsule lowered a harmful blood waste chemical (indoxyl sulfate) in people with chronic kidney disease after 16 weeks.

Lactobacillus acidophilus KBL409 improves serum indoxyl sulfate via gut microbial changes in a human study

Market readiness: 🙂🙂🙂🙂 (Human placebo-controlled trial, but this exact strain/product is not clearly a standard US consumer product yet.)

Good news: One short IV dose of DMT with structured support lowered depression scores more than placebo at 2 weeks, with benefits lasting up to 3 months for many people in this early trial.

A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial

Market readiness: 🙂🙂🙂 (Mid-stage clinical trial; would still need larger trials and FDA review before routine US use.)

Good news: New antiviral drug candidates worked in infected mice and could help even when the virus has resistance to older drugs.

From nicotine to SARS-CoV-2 antivirals with potent in vivo efficacy and a broad anti-coronavirus spectrum

Market readiness: 🙂 (Preclinical results in cells and mice; not yet proven in humans.)

Good news: In early lab and mouse tests, namodenoson slowed fat-cell growth and helped mice gain less weight, pointing to a possible new obesity treatment path later on.

The anti-obesity effect of namodenoson, an A3 adenosine receptor agonist

Market readiness: 🙂 (Preclinical for obesity; needs human obesity trials.)

Thank you for taking the time to take care of yourself and your loved ones.